KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Sells $50,121.28 in Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin L. Palleiko sold 5,104 shares of KalVista Pharmaceuticals stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $9.82, for a total transaction of $50,121.28. Following the completion of the transaction, the chief executive officer now owns 278,855 shares in the company, valued at approximately $2,738,356.10. This trade represents a 1.80 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

KalVista Pharmaceuticals Price Performance

Shares of NASDAQ KALV opened at $10.64 on Friday. KalVista Pharmaceuticals, Inc. has a 1-year low of $7.30 and a 1-year high of $15.50. The company has a market capitalization of $525.83 million, a price-to-earnings ratio of -2.92 and a beta of 0.85. The business has a 50-day moving average of $8.84 and a 200-day moving average of $10.43.

KalVista Pharmaceuticals (NASDAQ:KALV) last released its quarterly earnings results on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.01. Research analysts expect that KalVista Pharmaceuticals, Inc. will post -3.56 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. SG Americas Securities LLC acquired a new position in shares of KalVista Pharmaceuticals in the third quarter worth about $153,000. China Universal Asset Management Co. Ltd. increased its holdings in KalVista Pharmaceuticals by 67.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,286 shares of the specialty pharmaceutical company’s stock worth $96,000 after purchasing an additional 3,328 shares during the last quarter. Emerald Mutual Fund Advisers Trust raised its position in shares of KalVista Pharmaceuticals by 23.0% in the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 650,980 shares of the specialty pharmaceutical company’s stock valued at $7,538,000 after purchasing an additional 121,615 shares in the last quarter. Emerald Advisers LLC boosted its stake in shares of KalVista Pharmaceuticals by 29.8% during the 3rd quarter. Emerald Advisers LLC now owns 835,988 shares of the specialty pharmaceutical company’s stock valued at $9,681,000 after buying an additional 192,091 shares during the last quarter. Finally, Quest Partners LLC acquired a new stake in shares of KalVista Pharmaceuticals during the third quarter worth approximately $175,000.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on KALV shares. Citizens Jmp raised KalVista Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 31st. Bank of America assumed coverage on KalVista Pharmaceuticals in a report on Wednesday, December 18th. They issued a “buy” rating and a $22.00 price objective on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of KalVista Pharmaceuticals in a report on Monday, December 9th. TD Cowen began coverage on shares of KalVista Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating and a $30.00 price target on the stock. Finally, JMP Securities began coverage on shares of KalVista Pharmaceuticals in a research report on Friday, January 31st. They set an “outperform” rating and a $19.00 price target on the stock. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $23.80.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).